Adjuvant PD-1 antibody

Phase 2

Adjuvant PD-1 antibody is one of 2 therapeutic programs targeting Recurrent Head and Neck Squamous Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Recurrent Head and Neck Squamous Cell CarcinomaNot yet recruiting

Recurrent Head and Neck Squamous Cell CarcinomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Recurrent Head and Neck Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

2 2

Adjuvant PD-1 antibody

YYanjie Zhang, MD

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 2Not yet recruiting

Recurrent Head and Neck Squamous Cell Carcinoma

NCT07751289

Clinical

Trials by Indication[1]

Recurrent Head and Neck Squamous Cell Carcinoma1 trial

Anti-PD-1 Therapy in Locoregionally Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: A Multicenter, Randomized Controlled Clinical Trial

Not yet recruiting·YYanjie Zhang, MD·Phase 2·NCT07751289·217 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Adjuvant PD-1 antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Adjuvant PD-1 antibody. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Yanjie Zhang, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: YYanjie Zhang, MD

Adjuvant PD-1 antibody

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Recurrent Head and Neck Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News